ProCE Banner Activity

Clinical Landscape of TROP-2–Targeted Therapy in Advanced/Metastatic NSCLC

Slideset

Review data on the role of TROP-2–targeted antibody–drug conjugates in the treatment of metastatic NSCLC. 

Released: June 21, 2024

Expiration: June 20, 2025

Share

Faculty

Edward B Garon

Edward B Garon, MD, MS

Professor
Director of Thoracic Oncology
David Geffen School of Medicine at UCLA
Co-Director of Signal Transduction and Therapeutics Program
Jonsson Comprehensive Cancer Center at UCLA
Los Angeles, California

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.

AstraZeneca

Daiichi Sankyo, Inc.